Sentence: The results of a randomized phase II trial have demonstrated that the addition of cetuximab to irinotecan in patients with irinotecan-resistant tumors represents another active treatment option for these patients .
Drug combination annotation:
[{'class': 'POS', 'spans': ['cetuximab', 'irinotecan'], 'is_context_needed': False}]